Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Tyra Biosciences reported Q1 financial results, ending the quarter with $383.5 million in cash and marketable securities, which provides a runway into the second half of 2028. The company advanced its dabogratinib program by dosing the first patient in the SURF303 study for LG-UTUC, with initial results expected in 2027, and remains on track for data readouts in SURF302 and BEACH301 later this year.
Key figures
- Drug Name
- dabogratinib
- Guidance
- Runway into second half of 2028
- Deal Value Usd
- 147900000
- Phase Of Trial
- Phase 2
- Shares Offered
- 4690532
- Net loss
- 39300000
- Ga expenses
- 8500000
- Rd expenses
- 33500000
- Atm proceeds
- 147900000
- Cash position
- 383500000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.